NewGenIvf Group Limited Class A ordinary shares
Here’s whether NewGenIvf Group Limited Class A ordinary shares (NIVF) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-14.38% over 10 days); RSI 27 — oversold; weak 1-year return of -99.9%; 3-month momentum negative (-68.6%); rising volume on a downtrend (distribution, 2.31x avg). Currently 99.9% off its 52-week high. Score: -7/7.
NIVF is trading below its 200-day MA ($37.45) — a key warning sign the longer-term trend is under pressure. An RSI of 26.6 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -99.9% compares to +27.9% for SPY (trailed the market by 127.8%). The current 99.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.